Investigating metabolic and epigenetic factors in childhood brain tumors
Targeting integrated metabolic and epigenetic pathways in childhood ependymomas
This study is looking at a type of brain tumor in kids called ependymomas, especially the ones that are tough to treat, to find out how changes in the body’s metabolism and genes might help these tumors grow, with the hope of discovering new treatments that could work better for young patients.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Michigan at Ann Arbor NIH-funded |
| Lab location | 1 site (Ann Arbor, United States) |
| Project ID | NIH-10895347 on NIH RePORTER |
What this research studies
This research focuses on childhood ependymomas, particularly those arising in the hindbrain, which are often resistant to standard treatments like surgery and radiation. The study aims to understand how metabolic processes and epigenetic changes contribute to the development of these tumors, especially in infants and young children. By examining the role of specific proteins and metabolites, the research seeks to uncover new therapeutic targets that could lead to more effective treatments. Patients may be involved in trials that explore innovative therapies based on these findings.
Who could benefit from this research
Good fit: Ideal candidates for participation are children diagnosed with ependymomas, particularly those under 11 years old.
Not a fit: Patients with ependymomas that do not exhibit the specific metabolic and epigenetic characteristics being studied may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatments for childhood ependymomas, improving survival rates and quality of life for affected children.
How similar studies have performed: While the specific approach of targeting metabolic and epigenetic pathways in childhood ependymomas is novel, similar strategies have shown promise in other cancer types.
Where this research is happening
Ann Arbor, United States
- University of Michigan at Ann Arbor — Ann Arbor, United States (Active)
Researchers
- Principal investigator: Venneti, Sriram — University of Michigan at Ann Arbor
- Study coordinator: Venneti, Sriram
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.